A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)

Trial Profile

A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms SELECTION
  • Sponsors Biogen Idec
  • Most Recent Events

    • 28 Apr 2017 Results examining degree of return of disease activity in patients with relapsing-remitting multiple sclerosis (RRMS) following discontinuation of treatment with daclizumab HYP (daclizumab) in SELECT/SELECTION Studies presented at the 69th Annual Meeting of the American Academy of Neurology
    • 21 Apr 2016 Results (pooled analysis of SELECT and SELECTION studies, n = 73) assessing effects of daclizumab HYP 150mg on total and differential lymphocyte populations presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 20 Apr 2016 A post-hoc analysis of results from SELECT and SELECTION trials presented at the 68th Annual Meeting of American Academy of Neurology (AAN)2016, according to a Biogen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top